Cargando…

Insulin Metabolism in Polycystic Ovary Syndrome: Secretion, Signaling, and Clearance

Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorder in women of reproductive age. Its heterogeneous clinical presentation is characterized by hyperandrogenemia, reproductive changes, polycystic ovary morphology, and insulin resistance (IR). The primary pathophysiolog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herman, Rok, Sikonja, Jaka, Jensterle, Mojca, Janez, Andrej, Dolzan, Vita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962893/ https://www.ncbi.nlm.nih.gov/pubmed/36834549 http://dx.doi.org/10.3390/ijms24043140

Ejemplares similares

SLC6A4 5HTTLPR Polymorphism Affects Insulin Secretion in Patients with Polycystic Ovary Syndrome
por: Šenk, Barbara, et al.
Publicado: (2018)

Prolactin in Polycystic Ovary Syndrome: Metabolic Effects and Therapeutic Prospects
por: Mastnak, Lara, et al.
Publicado: (2023)

Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives
por: Jensterle, Mojca, et al.
Publicado: (2022)

Genetic Variability in Antioxidative and Inflammatory Pathways Modifies the Risk for PCOS and Influences Metabolic Profile of the Syndrome
por: Herman, Rok, et al.
Publicado: (2020)

Assessment of Eating Disorders and Eating Behavior to Improve Treatment Outcomes in Women with Polycystic Ovary Syndrome
por: Kolnikaj, Tea Shehu, et al.
Publicado: (2022)

Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport
por: Herman, Rok, et al.
Publicado: (2022)

An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity
por: Ferjan, Simona, et al.
Publicado: (2019)

Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study
por: JENSTERLE, MOJCA, et al.
Publicado: (2016)

Effects of Mindfulness-Based Therapy on Clinical Symptoms and DNA Methylation in Patients with Polycystic Ovary Syndrome and High Metabolic Risk
por: Dema, Hana, et al.
Publicado: (2023)

Effects of metformin withdrawal after long and short term treatment in PCOS: observational longitudinal study
por: Kravos, Nika Aleksandra, et al.
Publicado: (2021)

Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin
por: Jensterle Sever, Mojca, et al.
Publicado: (2014)

Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort
por: Jensterle, Mojca, et al.
Publicado: (2019)

Impact of COVID-19 Pandemic on Disease Control Status and Quality of Life of Patients with Acromegaly
por: Herman, Rok, et al.
Publicado: (2022)

Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity
por: Hropot, Tim, et al.
Publicado: (2023)

The prevalence and characteristics of non-functioning and autonomous cortisol secreting adrenal incidentaloma after patients’ stratification by body mass index and age
por: Podbregar, Ana, et al.
Publicado: (2020)

Pathophysiologic Mechanisms of Insulin Secretion and Signaling-Related Genes in Etiology of Polycystic Ovary Syndrome
por: Shaaban, Zahra, et al.
Publicado: (2021)

Glucagon-Like Peptide 1 and Taste Perception: From Molecular Mechanisms to Potential Clinical Implications
por: Jensterle, Mojca, et al.
Publicado: (2021)

SARS-CoV-2 Omicron symptoms and adverse effects of GLP-1 RA therapy
por: Jensterle, Mojca, et al.
Publicado: (2022)

Semaglutide in Obesity: Unmet Needs in Men
por: Jensterle, Mojca, et al.
Publicado: (2023)

SUN-221 Effects of Liraglutide on Obesity-Associated Functional Hypogonadism in Men: A Randomized, Testosterone Replacement Treatment-Controlled Study
por: Jensterle Sever, Mojca, et al.
Publicado: (2019)

Polycystic Ovary Syndrome as Metabolic Disease: New Insights on Insulin Resistance
por: Genazzani, Alessandro D, et al.
Publicado: (2023)

Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review
por: Jensterle, Mojca, et al.
Publicado: (2022)

Insulin resistance and fertility in polycystic ovary syndrome.
por: Fica, S, et al.
Publicado: (2008)

The Lifestyle Modifications and Endometrial Proteome Changes of Women With Polycystic Ovary Syndrome and Obesity
por: Abdulkhalikova, D., et al.
Publicado: (2022)

Case Report: Multiple prolactinomas in a young man with Kallmann syndrome and familial hypocalciuric hypercalcemia
por: Jensterle, Mojca, et al.
Publicado: (2023)

Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial
por: Jensterle, Mojca, et al.
Publicado: (2017)

Defective insulin signaling and the protective effects of dimethyldiguanide during follicular development in the ovaries of polycystic ovary syndrome
por: Wang, Fan, et al.
Publicado: (2017)

Afamin serum concentrations are associated with insulin resistance and metabolic syndrome in polycystic ovary syndrome
por: Seeber, Beata, et al.
Publicado: (2014)

Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes
por: DiNicolantonio, James J, et al.
Publicado: (2022)

New markers of insulin resistance in polycystic ovary syndrome
por: Polak, K., et al.
Publicado: (2016)

Limitations of insulin resistance assessment in polycystic ovary syndrome
por: Lewandowski, Krzysztof C, et al.
Publicado: (2018)

Endocrine disorders after heart transplantation: national cohort study
por: Rakusa, Matej, et al.
Publicado: (2020)

The Role of Genetic Factors and Kidney and Liver Function in Glycemic Control in Type 2 Diabetes Patients on Long-Term Metformin and Sulphonylurea Cotreatment
por: Klen, Jasna, et al.
Publicado: (2014)

NLRP3 Inflammasome Polymorphism and Macrovascular Complications in Type 2 Diabetes Patients
por: Klen, Jasna, et al.
Publicado: (2015)

A Comparative Study on Insulin Secretion, Insulin Resistance and Thyroid Function in Patients with Polycystic Ovary Syndrome with and without Hashimoto’s Thyroiditis
por: Zhao, Hongli, et al.
Publicado: (2021)

Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study
por: Jensterle, Mojca, et al.
Publicado: (2015)

INDIVIDUALIZATION OF CUSTOM COMPOUNDED HORMONE THERAPY IN A PATIENT WITH CHEMOTHERAPY INDUCED PREMATURE OVARIAN INSUFFICIENCY AND IMPAIRED LIVER FUNCTION – CASE REPORT
por: Franić, Damir, et al.
Publicado: (2019)

Association between polycystic ovarian morphology and insulin resistance in women with polycystic ovary syndrome
por: Lee, Jeong Eun, et al.
Publicado: (2023)

Phenotype and Metabolic Disorders in Polycystic Ovary Syndrome
por: Głuszak, Olgierd, et al.
Publicado: (2012)

Metabolic effects of polycystic ovary syndrome in adolescents
por: Han, Yejin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nal0p2medj894r0mr7ce2lvlu7